Matthew Maxwell Donley Sells 65,902 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the transaction, the chief operating officer now owns 739,456 shares of the company’s stock, valued at $5,915,648. This represents a 8.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $8.19 on Friday. The firm has a 50-day simple moving average of $8.10 and a 200-day simple moving average of $7.86. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -54.60 and a beta of 1.22. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

A number of hedge funds have recently modified their holdings of AUPH. SBI Securities Co. Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $25,000. GF Fund Management CO. LTD. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $27,000. Tower Research Capital LLC TRC raised its position in shares of Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $31,000. Finally, Natixis acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $49,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.